Lexicon Pharmaceuticals, Inc.
LXRXStock
$2.24+91.30%52W
Market Cap$966.13M
P/E—
Div yield—
Beta1.02
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)78.57%
Price vs S&P 500 (4W)12.22%
VGM Score64.74
Market Capitalization$966.13M
Earnings Surprise History
Q1 260.00est. -0.04
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LXRXLexicon Pharmaceuticals, Inc. | D | A | B | $2.24 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Lexicon Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics. Its pipeline includes LX9211 and LX9851, oral drug candidates, with LX9851 targeting obesity and associated cardiometabolic disorders. The company focuses on commercializing treatments for significant unmet medical needs.